Natural Killer Cell Leukemia: Diagnosis, Pathogenesis and Treatment by Shoko Kobayashi
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
Natural Killer Cell Leukemia: 
Diagnosis, Pathogenesis and Treatment 
Shoko Kobayashi 
Kohseichuo Hospital 
Japan 
1. Introduction 
Natural Killer(NK) cell nenoplasm is heterogeneous disease group. In the latest World 
Health Organization(WHO) classification of tumors of hematopoietic and lymphoid 
tissue(2008), disease entities considered as NK cell deviation are 1) Aggressive NK cell 
leukemia (ANKL), 2) NK cell lymphoblastic leukemia/lymphoma, 3) Extranodal NK/T-cell 
lymphoma, nasal. While several NK related diseases are proposed and investigated actively, 
optical treatment of NK cell neoplasms remains uncertain. However, several new 
chemoagents and transplantation are now in progress. 
2. Natural killer cell 
2.1 Definition 
Natural killer(NK) cells are the first lymphoid cells deployed in the defense against tumors 
and viral infection(Sun, 2010). Their activity is regulated by the interplay between inhibitory 
receptors, most of which recognize MHC class I molecules on target cells, and activating 
receptors which bind various ligands. Because NK cells originate from progenitor cells that 
can give rise to either NK or T cells; NK cells are phenotypically and immunologically 
similar to T cells. NK cells express T cell-associated markers, including CD2, cytoplasmic 
CD3(cCD3), CD7 and CD8, subsets of cytotoxic T cells and also express the NK-associated 
markers, CD16, CD56 and CD57. NK cells do not rearrange the T-cell receptor (TCR) genes. 
Early in development, NK-cell progenitors express no specific markers. Some markers that 
might be considered relatively more specific with NK progenitors, such as CD94 or CD161 
are no commonly tested. 
Important inhibitory receptors are members of the immunoglobulin-like receptor (KIR) 
family as well as CD94/NKG2 heterodimers. Examples for activating receptors are 
NKG2D (CD314), DNAM-1 (CD226) and the well-characterized natural cytotoxicity 
receptors (NCRs), NKp30(CD337), NKp44 (CD336) and NKp46 (CD335). Activating 
receptors such as NKG2D, recognize ligands that are not usually expressed by healthy 
cells but rather expressed by infected cells. The inhibitory receptors of NK cells interact 
with specific MHC class I molecules; for example, CD94/NKG2 binds to HLA-E, and KIR 
binds to HLA-B. The major constituents of cytotoxic granules are perforin and  
granzyme B.  
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2.2 Development 
Because NK cells exhibit considerable immunophenotypic similarity to T cells, they are 
thought to originate from a bipotent NK/T-progenitor cell. Moreover, human CD34(+) 
hematopoietic progenitors develop into NK cells in vitro in the presence of cytokines, 
hydrocortisone and stromal cells through the recruitment of myeloid precursors(Grzywacz, 
2011). Cells at more advanced stages of myeloid differentiation (those with higher levels of 
CD13 and macrophage colony-stimulating factor receptor [M-CSFR]) could also differentiate 
into NK cells in the presence of cytokines (interleukin-7, interleukin-15, stem cell factor, and 
fms-like tyrosine kinase-3 ligand), stromal cells, and hydrocortisone. NK cells derived from 
myeloid precursors (CD56(-)CD117(+)M-CSFR(+)) showed more expression of KIR. 
3. Natural killer cell neoplasm 
3.1 Diagnosis 
Accurate diagnosis of NK-cell neoplasm requires analysis of clinical presentation and of 
cell/tumor morphology, immunophenotype, and genotype(Oshimi, 2007). Expression of at 
lease one NK cell marker(CD56, CD16, or CD57), lack of expression of surface CD3, B-cell 
antigen(CD19, ad CD20) and MPO and other lineage markers and/or TCR Ig genes in 
germline configuraion in tumors are diagnostic factors. During the early stages of NK cell 
neoplasm, tumor cells do not express any tumor-specific markers or they express markers 
also found in T cell acute lymphoblastic leukemia (ALL), including CD7, CD2, CD5, and 
cCD3. Therefore it is difficult to distinguish between T- cell ALL and NK-cell tumors may be 
difficult. Later-stage but more specific markers, such as CD16, are rarely expressed in NK 
cell leukemia while some markers, such as CD94 and CD161, that might be considered 
relatively more specific expressed on NK progenitors. However, even now, it is difficult for 
us to distinguish NK cell neoplasm from myeloid neoplasms and T-cell neoplasms. It is 
hoped that wider availability of more specific NK markers including panels of antibodies 
against KIRs. 
3.2 Classification 
In the latest World Health Organization(WHO) classification of tumors of hematopoietic 
and lymphoid tissues(2008), acute leukemia with phenotype of NK cells includes(Swerdlow, 
2008); 1) Aggressive NK cell leukemia (ANKL) and 2) NK cell lymphoblastic 
leukemia/lymphoma. Other NK cell neoplasm and related disease are reported in literature; 
1) extranodal NK/T-cell lymphoma, nasal, 2) Myeloid/NK leukemia, and 3) Other CD56-
positive neoplasm(Oshimi, 2007). 
3.2.1 Aggressive NK cell leukemia (ANKL) 
ANKL is a catastrophic disease(Suzuki, 2010; Ham, 2010). ANKL has no gender preference, 
with the median age of presentation being in the third decade. ANKL is more prevalent 
among Asians than other ethnic populations. Circulation neoplastic cells varying 
morphologically form large granular lymphocytes to frank blast, may be present despite 
treatment. The neoplastic cells are CD2+, surface CD3-, CD3e+, CD56+, and positive for 
cytotoxic molecules. Immunophenoytpe is identical to that of extranodal type is identical to 
that of extranodal NK/T-cell lymphoma, except that CD16 is frequently positive. Patients 
have generally only been unwell for a few weeks, presenting with significant weight loss, 
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jaundice and a high fever. Skin infiltration, lymphoadenopaty and hepatosplenomegaly are 
common. Severe anemia and throm Survival measured in some weeks. It is unclear whether 
aggressive NK-cell leukemia represents the leukemic counterpart of extranodal NK/T-cell 
lymphoma. Strong association with Epstein-Barr virus(EBV) suggests a mechanism of 
pathogenesis. 
3.2.2 NK cell lymphoblastic leukemia/lymphoma 
This neoplasm has been very difficult to define, because of considerable confusion in the 
literature(Swerdlow, 2008). WHO proposed that the diagnosis of precursor NK 
lymphoblastic leukemia/lymphoma may be considered in a case that expresses CD56 along 
with immature T cell-associated markers such as CD7, CD2 or even including cCD3, 
provided the tumor lacks B-cell and myeloid markers, and that theT cell and Ig receptor 
genes are in the germline configuration. Clinical features associated with these NK 
neoplasms are not well known. Previously we reported a 69-year-old man with NK cell 
lymphoblastic leukemia/lymphoma(Kobayashi, 2010). He presented with skin and bone 
marrow involvement upon initial diagnosis. Neoplastic cells were blastic in appearance with 
a CD3-, CD4-, CD8-, CD7-, CD16-, CD56+ and HLA-DR+ phenotype. Molecular studies 
showed germline configuration of both immunoglobulin H and T cell receptor genes, and 
negative results for Epstein-Barr virus-encoded small RNA (EBER). 
Optimal treatment of this disease has not been determined. The presence or absence of P-
glycoprotein(P-gp) on tumor cells is one factor that influences the choice of anti-cancer 
drugs(Egashira, 1999). 
3.2.3 Extranodal NK/T-cell lymphoma, nasal 
Extranodal NK cell lymphomas(ENKL) are more prevalent in Asia, Mexico, and Central and 
South America and are characterized by extranodal presentation and an aggressive clinical 
course(Schmitt, 2011; Yok-Lam, 2011; Suzuki, 2009; Ng, 2011). Two types of ENKL (nasal 
and extranasal ENKL) were reported. Because they share the same histology, the WHO 
classification groups both nasal and extranasal ENKL in the same category. However, nasal 
and extranasal ENKL have different clinical manifestations, treatment approaches and 
prognosis. 
International Peripheral T-cell lymphoma Project showed the clinical characteristics of both 
NK cell lymphoma among 1153 new adult cases of peripheral/T-cell lymphoma at 22 
centers in 13 countries(Au, 2009). 136 cases (11.8%) of extranodal NK/T-cell lymphoma were 
identified (nasal 68%, extranasal 26%, aggressive/unclassifiable 6%). There were no 
differences in age, sex, ethnicity, or immunophenotypic profile between the nasal and 
extranasal cases, but the latter had more adverse clinical features. The median overall 
survival (OS) was better in nasal compared with the extranasal cases in early- (2.96 vs 0.36 
years) and late-stage disease (0.8 vs 0.28 years). Among nasal cases, both the International 
Prognostic Index and Korean NK/T-cell Prognostic Index were prognostic. In addition, Ki67 
proliferation greater than 50%, transformed tumor cells greater than 40%, elevated C-
reactive protein level (CRP), anemia (< 11 g/dL) and thrombocytopenia (< 150 x 10(9)/L) 
predicts poorer OS for nasal disease. No histologic or clinical feature was predictive in 
extranasal disease.  
The strong association of EBV was observed, with type II latency pattern(EBNA-1+, EBNA-
2+, LMP1+), and commonly showed a 30-base pair deletion in the latent membrane protein-
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1(LMP-1) gene(Swerdlow, 2008). Genome-wide gene expression profiling of extranodal 
NK/T lymphoma(NKTL) showed genes differentially expressed between NKTL and normal 
NK cells revealed significant enrichment for cell cycle-related genes and pathways, such as 
PLK1, CDK1, Aurora-A, activation of Myc and nuclear factor kappa B (NF-κB), and 
deregulation of p53. A significant percentage of NKTLs (n = 33) overexpressed c-Myc 
(45.4%), p53 (87.9%), NF-κB p50 (67.7%) and survivin(97%)(Huang, 2010). It is possible to 
propose a model of NKTL pathogenesis where deregulation of p53 together with activation 
of Myc and NF-κB, possibly driven by EBV LMP-1, results in the cumulative up-regulation 
of survivin. Down-regulation of survivin with Terameprocol (EM-1421, a survivin inhibitor) 
results in reduced cell viability and increased apoptosis in tumour cells, suggesting that 
survivin may be a potential oncoregulative gene in NKTL. Overexpressed PDGFRA, 
deregulation of the AKT, JAK-STAT, and nuclear factor-kappaB , RelA and recurrent copy 
number aberrations (AKT3 [1q44], IL6R [1q21.3], CCL2 [17q12], TNFRSF21 [6p12.3]) was 
reported (Ng, 2011).  
The common cytogenetic abnormality of ENKL is del(6)(q21q25)or i(6)(p10). Integrative 
analysis also evidenced deregulation of the tumor suppressor HACE1 in the frequently 
deleted 6q21 region(Zhang, 2007). HACE1 is novel E3 ubiquitin ligase, frequently 
downregulated in human tumors. Genetic inactivation of HACE1 in mice results in the 
development of spontaneous, late-onset cancer. A second hit from either environmental 
triggers or genetic heterozygosity of another tumor suppressor, p53, markedly increased 
tumor incidence in a Hace1-deficient background. Re-expression of HACE1 in human tumor 
cells directly abrogates in vitro and in vivo tumor growth, whereas downregulation of 
HACE1 via siRNA allows non-tumorigenic human cells to form tumors in vivo. 
Mechanistically, the tumor-suppressor function of HACE1 is dependent on its E3 ligase 
activity and HACE1 controls adhesion-dependent growth and cell cycle progression during 
cell stress through degradation of cyclin D1.  
3.2.4 Myeloid/NK leukemia 
The entity of myeloid/NK-cell acute leukemia may be of precursor NK origin, however 
myeloid/NK-cell acute leukemia cannot be distinguished form acute myeloid leukemia 
with minimal differentiation(Tang, 2008). Reportedly, myeloid/NK cell precursor acute 
leukemia (MNKPL) give rise to blasts that are cytochemically myeloperoxidase negative 
(MPO(-)) and phenotypically CD56(+)CD3(-)CD7(+)CD34(+) and have myeloid 
antigens(Guan, 2011). In contrast, myeloid/NK cell acute leukemia (MNKL) give rise to 
blasts that are cytochemically MPO(dim) and phenotypically CD56(+), CD16(-), CD3(-), 
CD)33(+)HLA-DR(-). Several cases of childhood NK leukemia, four MNKPL and one 
MNKL, were reported in China. The extramedullary involvement that usually occurs in 
cases of adult MNKPL was not observed in these cases of childhood MNKPL. Those with 
MNKPL were treated using a protocol designed for childhood high-risk ALL containing 
cytarabine, mitoxantrone, etoposide, l-asparaginase, and methotrexate depending on the 
myeloid and lymphoid characteristics of the MNKPL. They responded slowly to 
chemotherapy and were in complete remission (CR), except one who died from pneumonia 
while in CR. Therefore, protocols that combine agents used against acute myeloid leukemia 
with agents used against ALL are apparently effective against childhood MNKPL. 
A 6-year-old Japanese child was reported to be myeloid/NK cell precursor acute leukemia 
(MNKL)(Shiba 2010). The patient was treated by cord blood transplantation from an HLA 1-
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locus mismatched unrelated donor after chemotherapy comprising cytosine arabinoside, 
idarubicin, etoposide, and L-asparaginase. The nonsense mutation, C7412A, resulting in 
S2471X, where X is a terminal codon, in the PEST domain of NOTCH1 were observed, 
suggesting a possible role in the leukemogenesis of MNKL.  
In addition, CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia was 
proposed(Suzuki, 1997; Suzuki, 2005, Piichowska, 2007). Striking extramedullary 
involvement was evident at initial presentation, with peripheral lymphadenopathy and/or 
mediastinal masses. Expression of CD7, CD33, CD34, CD56, and frequently HLA-DR, but 
not NK, T-cell, and B-cell markers was observed. Myeloperoxidase was negative. Almost all 
presented germline configurations of the TCR  and  chain genes and Ig heavy chain gene. 
Despite intensive chemotherapy, including allogeneic bone marrow transplantation, most 
persued fatal courses within 41 months. Forty-nine patients with CD7(+) CD56(+) acute 
myeloid leukemia were analyzed(Suzuki, 1997). There were 17 patients with a classification 
of M0, which corresponded to MNKPL, and 32 patients with an AML classification other 
than M0 (i.e., M1-M7; 9 each for M1 and M2, 1 for M3, 3 for M4, 4 for M5, and 6 for M7). The 
age distribution was similar in both groups, but the MNKPL group, i.e., CD7(+) CD56(+) 
M0, had significantly more males than the CD7(+) CD56(+) M1-M7 group. The disease 
localization and the hematological manifestations were different between the groups; 
specifically, the patients with MNKPL presented with lower white blood cell counts and 
fewer circulating leukemic blasts, less anemia, less thrombocytopenia, and more frequent 
extramedullary involvement. The prognosis was poor in both groups. These findings 
suggest that extramedullary involvement of myeloid/NK cell precursor acute leukemia is 
not directly derived from the presence of CD7 and CD56 antigens on leukemic cells. The 
poor prognosis of CD7(+) CD56(+) M1-M7 suggests that this phenotype may act as a 
prognostic factor for AML, but this assertion should be confirmed in further clarification. 
3.2.5 Other CD56 positive neoplasm 
CD56 has been recognized as a sensitive marker for NK cells and has become popular for 
identifying NK cell neoplasms. Approximately 200 CD56+ hematopoietic neoplasms with 
immature features have been reported in the literature under different names. It is difficult 
to determine whether these tumors are of a truly derived from NK cells. For example, 
tumors that were previously defined as “blastic NK lymphoma” are now classified into two 
entities: 1) blastic plasmacytoid dendritic cell neoplasm; and 2) NK cell lymphoblastic 
leukemia/lymphoma(Pilichowska, 2007). The identification of the cell type, blastic 
plasmacytoid dendritic cell led to the definition of a new disease entity of blastic 
plasmacytoid dendritic cell neoplasm.  
Recently a new disease category, NK-cell enteropathy, was proposed based eight patients 
with atypical NK-cell lymphoproliferative lesions that mimicked NK- or T-cell 
lymphoma(Mansoor, 2011). These patients presented with vague gastrointestinal symptoms 
and with lesions involving stomach, duodenum, small intestine, and colon. Biopsies 
revealed a mucosal infiltrate of atypical cells with an NK-cell phenotype (CD56(+)/TIA-
1(+)/Granzyme B(+)/cCD3(+)).EBER was negative, and TCR-Ǆ gene rearrangement showed 
no evidence of a clonal process. Some patients received aggressive chemotherapy followed 
by auto HSCT. Five patients were followed without treatment. However, no patient 
developed progressive disease or died of lymphoma.  
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While a distinct disease entity, “lymphomatoid gastropahty (LyGa)”, was proposed based 
on the analysis of 10 other patients with unrecognized self-limited NK-cell proliferation in 
the stomach(Takeuchi, 2010). Endoscopy showed elevated lesion(s). The cells were CD2+/−, 
sCD3−, cCD3+, CD4−, CD5−, CD7+, CD8−, CD16−, CD20−, CD45+, CD56+, CD117−, CD158a−, 
CD161−, T cell–restricted intracellular antigen-1+, granzyme B+, perforin+, Epstein-Barr early 
RNA−, T-CR ǂǃ−, and TCR Ǆǅ−. Most lesions underwent self-regression. Three cases 
relapsed, but none of the patients died. LyGa is proposed as a pseudomalignant process 
because of its clinical characteristics.  
4. Pathogenesis  
4.1 EBV 
NK cell neoplasms are strongly related with latent EBV infection. 
EBV is a ubiquitous human gamma-herpesvirus that preferentially establishes latent 
infection in viral infected B-lymphocytes(Pizzigallo, 2010). The structure of EBV shows a 
linear double-stranded DNA, an capside, 162 capsomers and an envelope. The EBV genome 
encodes nearly 100 viral proteins. During viral replication, these proteins play a 
fundamental role in regulating the expression of viral genes, replicating viral DNA, forming 
structural components of the virion, modulating the host immune response, and forcing 
these cells immortal. The receptor for the virus on epithelial cells and B lymphocytes is the 
CD21 molecule, which is also the receptor for the C3d component of complement. The major 
histocompatibility complex (MHC) class II molecule serves as cofactor for the infection of B 
cells.  
Cellular infection from EBV could have two possible outcomes. A lytic infection occurs 
wherein virions are produced and the host cell is lysed. Lytic infection typically occurs in 
epithelial cells and partly in plasma cells. EBV may induce a latent infection by generating 
an episome, the circular EBV genome, that is located in the nucleus of host lymphocytes. 
The response of CD8-positive (CD8+) cytotoxic T-cells is crucial to control the primary 
infection, and these cells show a predominant role in infectious mononucleosis(IM), being 
present in the circulation and tissues in very high numbers. These cells probably give rise to 
most of the symptoms and signs of IM as a result of massive production of cytokines, 
including lymphotoxin, tumor necrosis factor-ǂ, interleukin (IL)-1ǃ and IL-6. That CD8+ T 
cells are essential for recovery from IM is exemplified by the consequence of primary EBV 
infection. 
The latent viral infections in which the virus persists in a form unable to be identified 
through standard methods. The mechanisms of EBV latency have been carefully examined 
both because they represent the virus strategy to elude the response of the immune system 
of the host, and because they are correlated with those oncologic conditions associated to the 
viral persistence, particularly lymphoma and lymphoproliferative disorders. During latency, 
resting memory B cells represent the site of persistence of EBV within the body. In normal 
adults, from 1 to 50 B cells per million in the circulation are infected with EBV, and the 
number of latently infected cells remains stable over years. 
There are different programs of EBV latency that are probably associated with different viral 
strategies aimed at surviving host immunological responses, and some of these programs 
have been correlated with malignancies typically associated with viral persistence. Four 
latency programs was proposed(Table I, II). In the first form, only EBNA-1 and EBER are 
expressed, whereas in the second form EBNA-1, LMP-1, LMP-2, and EBER are expressed. In 
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the third pattern, all the latency genes are expressed. A fourth pattern of latency is seen in B 
cells obtained from the peripheral blood of healthy persons infected with EBV in the past, in 
which only EBER and LMP-2, and in some studies, EBNA-1 RNA have been detected. 
Burkitt’s lymphoma is characterized by the type 1 of the latency program, the 
nasopharyngeal carcinoma, Hodgkin’s lymphoma and peripheral T cell lymphoma by the 
type 2. The type 3 of the latency program should characterize other lymphoproliferative 
diseases induced by EBV in immunocompromised hosts as well as the IM. These 
mechanisms are involved virological factors associated with EBV antigenic characteristics, 
host factors with particular regard to the genetic and immune systems and environmental 
co-factors. Of the nearly 100 viral genes that are expressed during replication, only 10 are 
expressed in latently infected B cells in vitro: two types of nontranslated RNA, six nuclear 
protein and two membrane proteins. Among several viral proteins, EBNA1 and LMP1 are 
important in tumorigenesis. 
4.1.1 EBV nuclear antigen 1 (EBNA-1) 
EBV latent infection, and its associated oncogenic potential, is dependent on genome 
maintenance functions of EBV nuclear antigen 1 (EBNA-1), one of six EBNAs expressed 
from a common promoter(Wp and then Cp) upon infection of naive B cells. EBNA1 initiates 
latent viral replication in B cells maintains the viral genome copy number, and regulates 
transcription of to the EBV-encoded latent genes. These activity are mediated through the 
ability of EBNA1 to bind viral-DNA. 
Resistance to apoptosis is an important in tumorigenic process. EBNA1 forms a complex 
with Sp1 or Sp1-like proteins bound to their cis-element at the survivin promoter. This 
interaction enhances the activity of the complex and up-regulates survivin. Knockdown of 
survivin and EBNA1 showed enhanced apoptosis in EBV -infected cells and thus supports a 
role for EBNA1 in suppressing apoptosis in EBV-infected cells(Ian, 2008). 
Cell proliferation was inhibited in an EBV-positive ENKL cell line by RNA interference 
(RNAi)-mediated silencing of EBNA1. Silencing of EBNA1 expression by RNAi inhibited 
cell growth, increased the expression of the p27 protein, and caused cell cycle arrest in G(1).  
 
Gene Protein Function 
BKRF1 EBNA-1 viral genome maintenance 
  transcription of EBV latent genes 
  B cell immortalization 
BKRF1 EBNA-2 B cell immortalization 
BLF-BERF EBNA-3 B cell immortalization 
BNLF1 LMP-1 oncoprotein 
BNLF2 LMP-2 prevents cell lytic-cycle entry 
BCRF1 EBER1,2 regulates PKC activity 
BARF0 Bam HIA transcripts not known 
Table 1. EBV latent viral genes 
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4.1.2 Latent membrane protein-1(LMP-1) 
EBV encodes a viral oncogene, LMP1 (latent membrane protein-1). LMP1 is expressed in 
EBV-associated lymphoma and is essential for B-cell transformation and for disruption of 
cellular signal transduction(Dellis, 2009). LMP1 acts by constitutive activating multiple 
signaling pathway, including the NK-kB pathway. In extranodal NK/T-cell lymphoma, 
nasal type, deletion of 30 bp in the LMP-1 gene are reported, but the molecular and 
pathogenic significance of these deletions is not clear. 
 
 EBNA-1 EBNA-2 EBNA-3 LMP-1 LMP-2 EBER Disease 
Type 1 + - - - - + Burkitt's lymphoma 
Type 2 + - - + + + Nasopharyngea carcinoma 
       Hodgkin's disease 
Type 3 + + + + + + Lymphoproliferative disease 
       Infectious mononucleosis 
others + - - - + + Healthy carieer 
Table 2. Expression of EBV latent genes in disease 
4.2 Cytogenetics 
Several cytogenetic abnormalities have been reported in ENKL cases(Schmitt, 2011).  
Reported abnormal chromosomal gains are 1q21–q44, 2q13-q14, 2q31.1–q32.2, 6p25–p11.1, 
7q11.2–q34, 7q35-q36, 17q21.1, 20pter-qter、while abnormal chromosomal losses are 6q16–
q25, 11q23.1, 11q24-q25, 13q14.11, 17p13.3 
The genes for responsible for above abnormalities have been investigated and are 
speculated to be EBV LMP2-TR; survival/apoptosis related: CCND3, SERPINB9, FASL, or 
TNFAIP3; angiogenesis related: HGFR (MET), VEGFR2, VEGFA, or HIF1ǂ; cell signaling 
pathway related: JAK-STAT, AKT, NOTCH, WNT, or PDGF; tumor-suppressor gene 
related: del6q21(PRDM1, ATG5, AIM1, or HACE1); and other pathways/genes: TP53, TP73, 
or AURKA.  
5. Staging 
A standard staging system for NK-T-cell lymphomas is lacking. Moreover, the Ann-Arbor 
staging system is probably unsatisfactory for NK/T-cell lymphomas.  
Involvement of bone marrow(BM) is an important staging and prognostic factor(Huang, 
2005). A study was done to evaluate the use of EBER -1 in situ hybridization (EBER-1 ISH) 
to detect occult micrometastasis in the bone marrow (BM) of patients with nasal NK/T-
cell lymphoma. Conventional morphologic examinations failed to identify any lymphoma 
involvement in the BM specimens obtained at initial staging. However, some BM 
specimens were positive for EBER-1. A lower survival rate was seen in patients with BM 
positive for EBER-1-positive BM specimens, and only the BM EBER-1 ISH result was 
shown to be an independent variable predicting overall survival in stage I / II patients, 
suggesting that EBER-1 positivity in BM is the major determinant of a poor prognosis. 
These findings indicate that EBER-1-positive BM specimens are an important indicator of 
a poor prognosis, and based on this study, BM EBER-1 ISH evaluation is recommended 
for accurate staging. 
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6. Prognosis; Prognostic factors 
To improve the stratification of patients for treatment, some prognostic models have been 
applied to NK-cell neoplasms. 
The International Prognostic Index(IPI), taking into account the stage, age, performance 
status, number of extranodal sites and the LDH level, is evidently useful for assess the 
prognosis of patients with NK-cell lymphoma(Lee, 2006). 
Clinical features and prognosis of 22 with ANKL and 150 with ENKL patients was 
reviewed(Suzuki, 2010). The ENKLs consisted of 123 nasal and 27 extranasal (16 cutaneous, 
9 hepatosplenic, 1 intestinal and 1 nodal) lymphomas. Multivariate analysis showed that 
four factors (non-nasal type, stage, performance status and numbers of extranodal 
involvement) were significant prognostic factors. Using these four variables, an NK 
prognostic index was successfully constructed. Four-year overall survival of patients with 
zero, one, two and three or four adverse factors were 55%, 33%, 15% and 6%, respectively. 
Korean prognostic index (K-IPI) was analyzed as a prognostic model specifically for 
ENKL(Lee, 2006). Prognostic factors for survival were "B" symptoms, stage, LDH level, and 
regional lymph nodes. K-IPI identified four different risk groups: group 1, no adverse factor; 
group 2, one factor; group 3, two factors; and group 4, three or four factors. The K-IPI 
showed a superior prognostic discrimination when compared with the IPI. Notably, when 
the K-IPI system was used, 7% of patients were in group 1; 31% were in group 2; 20% were 
in group 3, and 22% were in group 4; in contrast, 81% of patients were categorized as low or 
low-intermediate risks using IPI. 
In nasal NK/T-cell lymphoma, measurement of circulating plasma EBV DNA is reportedly 
useful for evaluating the prognosis of patients(Hsieh, 2007). 
7. Treatment  
1 Chemotherapy 
a) L-asparaginase 
b) Methotrexate 
c) combination regimen SMILE 
2 Hematopoietic stem cell transplantation(HSCT) 
3 New therapeutic strategies 
a) Bortezomib 
b) Pegasparaginase 
c) Kinase inhibitor 
d) Antibody treatment 
4 Radiation 
 
Table 3. Treatment of NK neoplasm 
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7.1 Chemotherapy 
7.1.1 L-asparaginase containing regimen 
The poor treatment results of conventional chemotherapy reatments for NK cell neoplasm 
are often attributed to the high expression level of the drug-exporting protein P-
glycoprotein, which results in the multidrug-resistance(MDR) phenotype(Jaccard, 2009). L-
asparaginase(L-asp), an enzyme that hydrolyzes serum L-asp, induces asparagine starvation 
of tumors with low expression of asparagine synthetase. This results in rapid inhibition of 
protein synthesis and delayed inhibition of DNA and RNA synthesis in lymphocytes. 
Thirty-three Chinese patients with midline NK/T-cell lymphoma nasal-type were received 
L-asp based salvage regimen for 2 approximately 6 cycles (median 3 cycles) plus 
locoregional radiation. Seventeen of the 33 CHOP failures (51.5 %) (L-asp group) reached 
CR(Yong, 2006). The 5-year overall survival (OS) rates were 55.9% for L-asp group. On 
univariate analysis, disease stage, fever symptom and performance status were significant 
factors influencing overall survival. On multivariate analysis, only disease stage and fever 
symptom remained as independently significant factors influencing OS. 
The multicentric French retrospective study of 15 patients with relapsed, refractory, or 
disseminated disease, treated with L-asp - containing regimens(Jaccard, 2009). All but two of 
the patients had an objective response to L-asp-based treatment. Seven patients reached 
complete remission and only two relapsed. These data confirm the excellent activity of L-
asp-containing regimens in refractory extranodal NK/T-cell lymphoma and also aggressive 
NK-cell leukemia. The results indicated that L-asp based regimen might be a promising new 
salvage or even first-line chemotherapeutic regimen for NK-cell neoplasms.. 
7.1.2 Methotrexate (MTX) 
To overcome the drug resistance of P-glycoprotein, multiple clinical trials were conducted. 
We report a case of a 69-year-old man with NK cell lymphoblastic leukemia /lymphoma 
who was treated mainly with methotrexate (MTX) (Kobayashi, 2010). He presented with 
skin and bone marrow involvement at onset. Neoplastic cells were blastic in appearance 
with a CD3-, CD4-, CD8-, CD7-, CD16-, CD56+ and HLA-DR+ phenotype. Molecular studies 
showed germline configuration of both immunoglobulin JH and T cell receptor genes and 
negative results for EBER. He was treated with standard ALL-targeting induction therapy, 
followed by one cycle of high-dose MTX(HD-MTX) as consolidation therapy. However, the 
disease recurred during the standard ALL maintenance therapy. Three cycles of HD-MTX 
were effective in achieving a second complete remission and he then received low dose MTX 
as maintenance therapy. The disease remained well-controlled for 4 years. MTX is one 
component of SMILE (methotrexate, ifosfamide, dexamethasone, etoposide, L-asparaginase) 
therapy. This encouraging result warrants further investigation of MTX either as a single 
agent or in a combination regimen as a first-line treatment for patients with NK cell 
malignancies. 
7.1.3 Combination chemotherapy: SMILE 
Japanese investigators treated advanced extranodal NK lymphoma with SMILE 
(Methotrexate, Ifosfamide, Dexamethasone, Etoposide, L-asparaginase) therapy(Yamaguchi, 
2008). For newly diagnosed stage IV or relapsed/refractory ENKL, the overall response rate 
was 74% and the CR rate was 40%. 
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Another study with patients had newly diagnosed stage IV, relapsed or refractory diseases 
after first-line chemotherapy, were 15-69 years of age, and had satisfactory performance 
scores (0-2) (Jaccard, 2011). For the six enrolled patients, the overall response rate was 67% 
and the complete response rate was 50%. Its safety and efficacy require further evaluation. 
To explore an effective salvage regimen, phase I pilot study of combination chemotherapy 
with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD), which are 
unaffected by MDR1-encoded P-glycoprotein, was tested in 18 patients(Tsukune, 2010). 
Among them, eleven had T/NK-cell malignancies, six had B-cell malignancies, and one had 
a blastic plasmacytoid dendritic cell neoplasm. Of the 14 patients evaluated, three achieved 
CR, and four showed a partial response(PR). The overall response rate was 57%. All seven 
responders had T/NK-cell malignancies. MILD therapy was feasible and presented 
acceptable toxicity in patients with refractory or lethal lymphoid malignancies.  
7.2 Hematopoietic Stem Cell Transplantation (HSCT) 
Because of the poor prognosis, many groups have favored the use of early transplantation of 
NK-cel neoplasms (Murashige. 2005:Suzuki, 2006; Ennishi, 2011; Ichikawa, 2010). 
Autologous HSCT has been evaluated in stage I/II disease in first or second CR, or 
chemosensitive relapse, and primary or secondary refractory disease without marrow 
involvement. The disease status pre-HSCT significantly affected overall survival. For most 
patients with stage I/II disease, the definite advantage of auto HSCT in first CR is 
questionable. However, based on a retrospective analysis, auto HSCT may be beneficial in a 
subgroup of patients in CR1 who have a high risk of relapse. HSCT is generally indicated in 
lymphoma patients achieving second CR, however further controlled trials are required to 
examine whether this also applies to NK/T-cell lymphoma. There is no survival advantage 
of auto HSCT in patients with advanced or refractory disease. Allogeneic HSCT, with the 
potential benefit of graft-versus-lymphoma (GVL) effect, is an option for patients with 
advanced disease. The GVL effect is further enhanced by the expression of EBV antigen on 
tumor cells. Small series have shown that it is a potentially curative option.  
The retrospective analysis studied the potential survival benefits of HSCT for ENKL 
compared with a historical control group. Forty-seven patients from 3 previously published 
series of HSCT were matched according to NK/T cell lymphoma International Prognostic 
Index (NK-IPI) risk groups and disease status at transplantation. After a median follow-up 
of 116.5 months, the median survival time was not determined for the HSCT group, but it 
was 43.5 months for the control group. In patients who were in CR at the time of HSCT or at 
surveillance after remission, disease-specific survival rates were significantly higher in the 
HSCT group compared with the control group (disease-specific 5-year survival rate, 87.3% 
for HSCT vs 67.8% for non-HSCT). In contrast, in subgroup analysis on non-CR patients at 
the time of HSCT or non-HSCT treatment, disease-specific survival rates were not 
significantly prolonged in the HSCT group compared with the control group (1-year 
survival rate, 66.7% for HSCT vs 28.6% for non-HSCT). The impact of HSCT on the survival 
of all patients was significantly retained at the multivariate level with a 2.1-fold reduced risk 
of death. HSCT seems to confer a survival benefit in patients who attained CR on 
postremission consolidation therapy. These findings suggest that patients in CR with high 
NKIPI risk scores at diagnosis should receive full consideration for HSCT. 
Among NK neoplasm, ANKL is a highly aggressive lymphoproliferative disease. a few case 
reports have suggested that allo-HSCT can be curative. For example, a report of a young 
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woman with ANKL showing central nervous system invasion, who has been in complete 
remission for more than a year after allo-HSCT following two courses of intravenous 
chemotherapy and several rounds of intrathecal chemotherapy(Ichikawa, 2010). 
However, most of the reported cases have been performed from HLA-identical sibling 
donors, and data on alternative HSCT sources including matched unrelated donor and 
umbilical cord blood are very limited. 
7.3 Radiation 
For localized diseases, radiation therapy is reportedly effective. For example, the addition of 
radiotherapy for early-stage nasal NK cell lymphoma cases yielded survival benefit (P = 
.045)(Suzuki. 2010). 
7.4 New therapeutic strategies 
7.4.1 Bortezomib 
Basic studies showed that LMP1 activates nuclear factor-κB (NF-κB) and that NF-κB is 
activated in extranodal natural killer (NK)/T-cell lymphoma, nasal type(Shen, 2008). 
Bortezomib is known to be effective for diseases involving NF-κB activation, such as 
multiple myeloma. Recently, bortezomib was reported to induce apoptosis of EBV-
transformed B cells.  
Twenty three patients with previously untreated NK/T-cell lymphoma initially treated with 
cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP) or CHOP-based 
chemotherapy were examined by immunohistochemistry for three NF-κB subunits(p65, p50 
and p52), which are involved in either the canonical or alternative pathway. NF-κB 
activation through the alternative pathway is frequently observed in NK/T-cell lymphoma 
and associated with chemoresistance and poor survival. In vitro, bortezomib treatment 
decreased the viability of NK cell lines. The decreased viability in response to bortezomib 
treatment was abrogated by a pan-caspase inhibitor. Additionally, cleavage of caspases and 
polyadenosine diphosphate -ribose polymerase, increased expression of phosphorylated 
IκB, and decreased expression of inhibitor of apoptotic proteins were detected by 
immunoblotting in bortezomib-treated cell lines. Administration of bortezomib to 
peripheral blood mononuclear cells from two patients with EBV-associated 
lymphoproliferative diseases show a greater killing effect on EBV-infected cells. These 
results indicate that bortezomib killed T or NK lymphoma cells by inducing apoptosis. 
A Phase I study of Bortezomib + CHOP treatment were conducted with 13 patients with 
advanced, aggressive T-cell or NK/T-cell lymphoma(Lee, 2008). The overall CR rate in all 
patients was 61.5% and showed no severe side effects. Bortezomib can be safely combined 
with CHOP chemotherapy and constitutes an active regimen. 
7.4.2 Pegaspargase 
Pegaspargase selected the pegylated form to achieve more prolonged continuous 
asparagine depletion as well as for ease of administration as it requires only a single 
treatment every 2–3 weeks(Reyes, 2008). Pegaspargase were reported an effective 
treatment for two patients with aggressive, extended, and refractory to CHOP 
chemotherapy. Pegaspargase is worth considering development of combination regimens 
and possibly front-line regimens. 
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7.4.3 Kinase inhibitor 
The EBV oncoprotein LMP1 reportedly activates the phosphatidylinositol-3 kinase 
(PI3K)/Akt pathway to induce cell survival(Jeon, 2007). The intrinsic level of pAkt was 
higher in EBV-positive NK cells than in EBV-negative NK cells. Geldanamycin (GA) and its 
derivative, 17-allylamino-17- demethoxygeldanamycin (17-AAG), are PI3K and Akt 
inhibitors that exhibit anti-tumor activity by degrading HSP90 client proteins, including 
Akt. The administration of GA and 17-AAG resulted in apoptosis of NK cells, accompanied 
by Akt and pAkt down-regulation, caspase 3 activation, and mitochondrial membrane 
potential disruption. Apoptosis of NK cells was also induced by LY294002 (a PI3K inhibitor) 
or Akt inhibitor II. More results both in vitro and in vivo are necessary to determine the 
efficacy of kinase inhibitors for treating NK neoplasms. 
7.4.4 Antibody treatment 
The immunoconjugate I MGN901 (huN901-DM1; ImmunoGen, Cambridge, MA,USA) is 
composed of the composed of the humanized monoclonal IgG1 antibody, huN901, and the 
maytansinoid drug, DM1, which binds CD56 with high affinity(Ishitsuka, 2009). IMGN901 
is a tumour-activated prodrug because the conjugation of DM1 to huN901 renders the 
cytotoxic drug inactive until it reaches the target site. The conjugate is then internalized and 
releases DM1, which inhibits tubulin polymerization and causes cell death. IMGN901 has 
been demonstrated to be safe and show promising efficacy in small cell lung cancer, CD56-
positive small cell carcinoma and multiple myeloma in phase I/II clinical studies. An in 
vitro study demonstrated that IMGN901 was cytotoxic for a CD56-positive NK cell line and 
fresh tumour cells derived from a patient with an NK-cell malignancy in vitro. These results 
indicate that IMGN901 represents a promising novel and targeted approach to improve 
patient outcomes for patients with NK cell malignancies. The activity of IMGN901 should be 
further validated in clinical trials. 
8. Conclusion 
The classification of NK cell neoplasms with overlapping features will remain controversial, 
particularly when EBV is absent. In order to establish more definitive and widely accepted 
diagnostic criteria for NK-cell neoplasms, more accurate diagnostic tools are needed. For 
proper treatment stratification of NK cell neoplasms, randomized clinical trials are waited, 
although conducting meaningful clinical trials is difficult because NK-cell neoplasms are rare. 
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